Cargando…
Therapeutic efficacy of pyronaridine-artesunate (Pyramax(®)) against uncomplicated Plasmodium falciparum infection at Hamusit Health Centre, Northwest Ethiopia
BACKGROUND: Early case detection and prompt treatment are important malaria control and elimination strategies. However, the emergence and rapid spread of drug-resistant strains present a major challenge. This study reports the first therapeutic efficacy profile of pyronaridine-artesunate against un...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10276904/ https://www.ncbi.nlm.nih.gov/pubmed/37330475 http://dx.doi.org/10.1186/s12936-023-04618-y |
_version_ | 1785060177403183104 |
---|---|
author | Alebachew, Mihreteab Gelaye, Woyneshet Abate, Megbaru Alemu Sime, Heven Hailgiorgis, Henok Gidey, Bokretsion Haile, Mebrahtom Assefa, Gudissa Bekele, Worku Belay, Habtamu Parr, Jonathan B. Tasew, Geremew Mohammed, Hussein Assefa, Ashenafi |
author_facet | Alebachew, Mihreteab Gelaye, Woyneshet Abate, Megbaru Alemu Sime, Heven Hailgiorgis, Henok Gidey, Bokretsion Haile, Mebrahtom Assefa, Gudissa Bekele, Worku Belay, Habtamu Parr, Jonathan B. Tasew, Geremew Mohammed, Hussein Assefa, Ashenafi |
author_sort | Alebachew, Mihreteab |
collection | PubMed |
description | BACKGROUND: Early case detection and prompt treatment are important malaria control and elimination strategies. However, the emergence and rapid spread of drug-resistant strains present a major challenge. This study reports the first therapeutic efficacy profile of pyronaridine-artesunate against uncomplicated Plasmodium falciparum in Northwest Ethiopia. METHODS: This single-arm prospective study with 42-day follow-up period was conducted from March to May 2021 at Hamusit Health Centre using the World Health Organization (WHO) therapeutic efficacy study protocol. A total of 90 adults ages 18 and older with uncomplicated falciparum malaria consented and were enrolled in the study. A standard single-dose regimen of pyronaridine-artesunate was administered daily for 3 days, and clinical and parasitological outcomes were assessed over 42 days of follow-up. Thick and thin blood films were prepared from capillary blood and examined using light microscopy. Haemoglobin was measured and dried blood spots were collected on day 0 and on the day of failure. RESULTS: Out of 90 patients, 86/90 (95.6%) completed the 42-day follow-up study period. The overall PCR-corrected cure rate (adequate clinical and parasitological response) was very high at 86/87 (98.9%) (95% CI: 92.2–99.8%) with no serious adverse events. The parasite clearance rate was high with fast resolution of clinical symptoms; 86/90 (95.6%) and 100% of the study participants cleared parasitaemia and fever on day 3, respectively. CONCLUSION: Pyronaridine-artesunate was highly efficacious and safe against uncomplicated P. falciparum in this study population. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12936-023-04618-y. |
format | Online Article Text |
id | pubmed-10276904 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-102769042023-06-19 Therapeutic efficacy of pyronaridine-artesunate (Pyramax(®)) against uncomplicated Plasmodium falciparum infection at Hamusit Health Centre, Northwest Ethiopia Alebachew, Mihreteab Gelaye, Woyneshet Abate, Megbaru Alemu Sime, Heven Hailgiorgis, Henok Gidey, Bokretsion Haile, Mebrahtom Assefa, Gudissa Bekele, Worku Belay, Habtamu Parr, Jonathan B. Tasew, Geremew Mohammed, Hussein Assefa, Ashenafi Malar J Research BACKGROUND: Early case detection and prompt treatment are important malaria control and elimination strategies. However, the emergence and rapid spread of drug-resistant strains present a major challenge. This study reports the first therapeutic efficacy profile of pyronaridine-artesunate against uncomplicated Plasmodium falciparum in Northwest Ethiopia. METHODS: This single-arm prospective study with 42-day follow-up period was conducted from March to May 2021 at Hamusit Health Centre using the World Health Organization (WHO) therapeutic efficacy study protocol. A total of 90 adults ages 18 and older with uncomplicated falciparum malaria consented and were enrolled in the study. A standard single-dose regimen of pyronaridine-artesunate was administered daily for 3 days, and clinical and parasitological outcomes were assessed over 42 days of follow-up. Thick and thin blood films were prepared from capillary blood and examined using light microscopy. Haemoglobin was measured and dried blood spots were collected on day 0 and on the day of failure. RESULTS: Out of 90 patients, 86/90 (95.6%) completed the 42-day follow-up study period. The overall PCR-corrected cure rate (adequate clinical and parasitological response) was very high at 86/87 (98.9%) (95% CI: 92.2–99.8%) with no serious adverse events. The parasite clearance rate was high with fast resolution of clinical symptoms; 86/90 (95.6%) and 100% of the study participants cleared parasitaemia and fever on day 3, respectively. CONCLUSION: Pyronaridine-artesunate was highly efficacious and safe against uncomplicated P. falciparum in this study population. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12936-023-04618-y. BioMed Central 2023-06-17 /pmc/articles/PMC10276904/ /pubmed/37330475 http://dx.doi.org/10.1186/s12936-023-04618-y Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Alebachew, Mihreteab Gelaye, Woyneshet Abate, Megbaru Alemu Sime, Heven Hailgiorgis, Henok Gidey, Bokretsion Haile, Mebrahtom Assefa, Gudissa Bekele, Worku Belay, Habtamu Parr, Jonathan B. Tasew, Geremew Mohammed, Hussein Assefa, Ashenafi Therapeutic efficacy of pyronaridine-artesunate (Pyramax(®)) against uncomplicated Plasmodium falciparum infection at Hamusit Health Centre, Northwest Ethiopia |
title | Therapeutic efficacy of pyronaridine-artesunate (Pyramax(®)) against uncomplicated Plasmodium falciparum infection at Hamusit Health Centre, Northwest Ethiopia |
title_full | Therapeutic efficacy of pyronaridine-artesunate (Pyramax(®)) against uncomplicated Plasmodium falciparum infection at Hamusit Health Centre, Northwest Ethiopia |
title_fullStr | Therapeutic efficacy of pyronaridine-artesunate (Pyramax(®)) against uncomplicated Plasmodium falciparum infection at Hamusit Health Centre, Northwest Ethiopia |
title_full_unstemmed | Therapeutic efficacy of pyronaridine-artesunate (Pyramax(®)) against uncomplicated Plasmodium falciparum infection at Hamusit Health Centre, Northwest Ethiopia |
title_short | Therapeutic efficacy of pyronaridine-artesunate (Pyramax(®)) against uncomplicated Plasmodium falciparum infection at Hamusit Health Centre, Northwest Ethiopia |
title_sort | therapeutic efficacy of pyronaridine-artesunate (pyramax(®)) against uncomplicated plasmodium falciparum infection at hamusit health centre, northwest ethiopia |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10276904/ https://www.ncbi.nlm.nih.gov/pubmed/37330475 http://dx.doi.org/10.1186/s12936-023-04618-y |
work_keys_str_mv | AT alebachewmihreteab therapeuticefficacyofpyronaridineartesunatepyramaxagainstuncomplicatedplasmodiumfalciparuminfectionathamusithealthcentrenorthwestethiopia AT gelayewoyneshet therapeuticefficacyofpyronaridineartesunatepyramaxagainstuncomplicatedplasmodiumfalciparuminfectionathamusithealthcentrenorthwestethiopia AT abatemegbarualemu therapeuticefficacyofpyronaridineartesunatepyramaxagainstuncomplicatedplasmodiumfalciparuminfectionathamusithealthcentrenorthwestethiopia AT simeheven therapeuticefficacyofpyronaridineartesunatepyramaxagainstuncomplicatedplasmodiumfalciparuminfectionathamusithealthcentrenorthwestethiopia AT hailgiorgishenok therapeuticefficacyofpyronaridineartesunatepyramaxagainstuncomplicatedplasmodiumfalciparuminfectionathamusithealthcentrenorthwestethiopia AT gideybokretsion therapeuticefficacyofpyronaridineartesunatepyramaxagainstuncomplicatedplasmodiumfalciparuminfectionathamusithealthcentrenorthwestethiopia AT hailemebrahtom therapeuticefficacyofpyronaridineartesunatepyramaxagainstuncomplicatedplasmodiumfalciparuminfectionathamusithealthcentrenorthwestethiopia AT assefagudissa therapeuticefficacyofpyronaridineartesunatepyramaxagainstuncomplicatedplasmodiumfalciparuminfectionathamusithealthcentrenorthwestethiopia AT bekeleworku therapeuticefficacyofpyronaridineartesunatepyramaxagainstuncomplicatedplasmodiumfalciparuminfectionathamusithealthcentrenorthwestethiopia AT belayhabtamu therapeuticefficacyofpyronaridineartesunatepyramaxagainstuncomplicatedplasmodiumfalciparuminfectionathamusithealthcentrenorthwestethiopia AT parrjonathanb therapeuticefficacyofpyronaridineartesunatepyramaxagainstuncomplicatedplasmodiumfalciparuminfectionathamusithealthcentrenorthwestethiopia AT tasewgeremew therapeuticefficacyofpyronaridineartesunatepyramaxagainstuncomplicatedplasmodiumfalciparuminfectionathamusithealthcentrenorthwestethiopia AT mohammedhussein therapeuticefficacyofpyronaridineartesunatepyramaxagainstuncomplicatedplasmodiumfalciparuminfectionathamusithealthcentrenorthwestethiopia AT assefaashenafi therapeuticefficacyofpyronaridineartesunatepyramaxagainstuncomplicatedplasmodiumfalciparuminfectionathamusithealthcentrenorthwestethiopia |